BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33678480)

  • 21. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study.
    Daraï E; Dubernard G; Bats AS; Heitz D; Mathevet P; Marret H; Querleu D; Golfier F; Leblanc E; Rouzier R; Ballester M
    Gynecol Oncol; 2015 Jan; 136(1):54-9. PubMed ID: 25450151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymph Node Isolated Tumor Cells in Patients With Endometrial Cancer.
    Matsuo K; Chen L; Neuman MK; Klar M; Carlson JW; Roman LD; Wright JD
    JAMA Netw Open; 2024 Mar; 7(3):e240988. PubMed ID: 38497964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence patterns and prognostic factors in lymphovascular space invasion-positive endometrioid endometrial cancer surgically confined to the uterus.
    Sahin H; Meydanli MM; Sari ME; Kocaman E; Cuylan ZF; Yalcin I; Coban G; Özen Ö; Sirvan L; Güngör T; Ayhan A
    Taiwan J Obstet Gynecol; 2019 Jan; 58(1):82-89. PubMed ID: 30638487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion.
    Zahl Eriksson AG; Ducie J; Ali N; McGree ME; Weaver AL; Bogani G; Cliby WA; Dowdy SC; Bakkum-Gamez JN; Abu-Rustum NR; Mariani A; Leitao MM
    Gynecol Oncol; 2016 Mar; 140(3):394-9. PubMed ID: 26747778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Utility of Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer.
    Tanner EJ; Ojalvo L; Stone RL; Levinson K; Temkin SM; Murdock T; Vang R; Sinno AK; Fader AN
    Int J Gynecol Cancer; 2017 Sep; 27(7):1416-1421. PubMed ID: 30814241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
    de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
    Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The added value of sentinel node mapping in endometrial cancer.
    Kogan L; Matanes E; Wissing M; Mitric C; How J; Amajoud Z; Abitbol J; Yasmeen A; López-Ozuna V; Eisenberg N; Lau S; Salvador S; Gotlieb WH
    Gynecol Oncol; 2020 Jul; 158(1):84-91. PubMed ID: 32349874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultrastaging of 'negative' pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences.
    Gill SE; Garzon S; Multinu F; Hokenstad AN; Casarin J; Cappuccio S; McGree ME; Weaver AL; Cliby WA; Keeney GL; Mariani A
    Int J Gynecol Cancer; 2021 Dec; 31(12):1541-1548. PubMed ID: 34706876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.
    Touhami O; Grégoire J; Renaud MC; Sebastianelli A; Grondin K; Plante M
    Gynecol Oncol; 2018 Mar; 148(3):485-490. PubMed ID: 29290489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer.
    Montes de Oca MK; Albright BB; Secord AA; Havrilesky LJ; Moss HA
    Int J Gynecol Cancer; 2021 Dec; 31(12):1549-1556. PubMed ID: 34725205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
    Han KH; Kim HS; Lee M; Chung HH; Song YS
    Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China.
    Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
    BMC Cancer; 2022 Mar; 22(1):266. PubMed ID: 35287626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of adjuvant chemotherapy in patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and post-operative radiotherapy.
    Reshko LB; Gaskins JT; Dryden SM; Metzinger DS; Todd SL; Eldredge-Hindy HB; Silva SR
    Int J Gynecol Cancer; 2021 May; 31(5):694-701. PubMed ID: 33741653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indocyanine green fluorescence imaging of lymph nodes during robotic-assisted laparoscopic operation for endometrial cancer. A prospective validation study using a sentinel lymph node surgical algorithm.
    Hagen B; Valla M; Aune G; Ravlo M; Abusland AB; Araya E; Sundset M; Tingulstad S
    Gynecol Oncol; 2016 Dec; 143(3):479-483. PubMed ID: 27776838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A tumor board report of an 83-year-old woman with stage IB grade 3 endometrioid endometrial adenocarcinoma.
    Alimena S; Fiascone S; Krasner C; King M; Horowitz N
    Curr Probl Cancer; 2019 Oct; 43(5):443-449. PubMed ID: 30770127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of adjuvant treatment on survival in patients with 2023 FIGO stage IIC endometrial cancer: a retrospective analysis from two tertiary centers in Korea and Taiwan.
    Lee YY; Lai YL; Kim MS; Chang K; Kim HS; Cheng WF; Chen YL
    J Gynecol Oncol; 2024 May; 35(3):e33. PubMed ID: 38130137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A large multicenter propensity match study of sentinel lymph node biopsy feasibility in endometrioid variants of endometrial cancer.
    Capozzi VA; Rosati A; Vargiu V; Sozzi G; Cosentino F; Chiantera V; Scambia G; Berretta R; Fanfani F
    Eur J Surg Oncol; 2022 Jun; 48(6):1390-1394. PubMed ID: 35120817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: Results of a retrospective multicenter study.
    Raimond E; Ballester M; Hudry D; Bendifallah S; Daraï E; Graesslin O; Coutant C
    Gynecol Oncol; 2014 Jun; 133(3):506-11. PubMed ID: 24642092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
    Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
    Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can risk groups accurately predict non-sentinel lymph node metastasis in sentinel lymph node-positive endometrial cancer patients? A Turkish Gynecologic Oncology Group Study (TRSGO-SLN-004).
    Altin D; Taskin S; Tokgozoglu N; Vatansever D; Guler AH; Gungor M; Tasci T; Turan H; Kahramanoglu I; Yalcin I; Celik C; Kose F; Ortac F; Arvas M; Ayhan A; Taskiran C
    J Surg Oncol; 2021 Feb; 123(2):638-645. PubMed ID: 33259650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.